Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 933527, "name": "Aarey Drugs", "stock_name": "Aarey Drugs", "full_name": "Aarey Drugs & Pharmaceuticals Ltd", "name_url": "stocks-analysis/aarey-drugs", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "90.94", "chg": 3.43, "chgp": "3.92%", "dir": 1, "prev_price": "87.51", "mcapval": "255.00 Cr", "mcap": "Micro Cap", "scripcode": 524412, "symbol": "AAREYDRUGS", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 49, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE198H01019", "curr_date": "Jun 23, 03:30 PM", "curr_time": "19:36 PM", "last_traded_at": "Jun 23, 03:30 PM IST", "bse_nse_vol": "1.23 lacs", "exc_status": "Active", "traded_date": "Jun 23, 2026", "traded_date_str": "2026 06 23", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aarey-drugs-933527-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Aarey Drugs & Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/aarey-drugs-pharmaceuticals-ltd-is-rated-hold-4069021", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_mojoScore_4069021.png", "date": "2026-06-23 10:10:04", "description": "Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook." }, { "title": "Aarey Drugs & Pharmaceuticals Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight", "link": "https://www.marketsmojo.com/news/stocks-in-action/aarey-drugs-pharmaceuticals-ltd-hits-lower-circuit-amid-heavy-selling-pressure-4055726", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_stocks_hitting_lower_circuit_4055726.png", "date": "2026-06-16 10:00:18", "description": "At Rs 75.39, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 16 Jun 2026, with unfilled sell orders and a frozen price, signalling a day dominated by supply overwhelming demand." }, { "title": "Aarey Drugs Gains 1.00%: 4 Key Factors Driving the Week’s Mixed Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/aarey-drugs-gains-100-4-key-factors-driving-the-weeks-mixed-momentum-4052110", "imagepath": "", "date": "2026-06-13 16:25:55", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Strong quarterly turnaround reported with record net sales and profits</p>\n <p><strong>1 June:</strong> Downgrade to Strong Sell amid mixed financial and technical signals</p>\n <p><strong>2 June:</strong> Valuation shift prompts upgrade from Strong Sell to Hold</p>\n <p><strong>5 June:</strong> Week closes at Rs.77.52, up 1.00% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.76.75</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close<..." }, { "title": "Aarey Drugs & Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/aarey-drugs-pharmaceuticals-ltd-is-rated-hold-4048969", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_mojoScore_4048969.png", "date": "2026-06-12 10:10:05", "description": "Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Below All Moving Averages and Now at Lower Circuit: Aarey Drugs & Pharmaceuticals Ltd Loses 4.7% in a Single Session", "link": "https://www.marketsmojo.com/news/stocks-in-action/aarey-drugs-pharmaceuticals-ltd-hits-lower-circuit-amid-heavy-selling-pressure-4046652", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_stocks_hitting_lower_circuit_4046652.png", "date": "2026-06-11 11:00:16", "description": "At Rs 74.51, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 11 Jun 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock." }, { "title": "Aarey Drugs & Pharmaceuticals Ltd: Valuation Shift Signals Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/aarey-drugs-pharmaceuticals-ltd-valuation-shift-signals-renewed-price-attractiveness-4029413", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_valuationdot_4029413.png", "date": "2026-06-02 08:04:16", "description": "Aarey Drugs & Pharmaceuticals Ltd has witnessed a notable transformation in its valuation metrics, shifting from a previously risky profile to one deemed attractive by recent assessments. This change, coupled with a significant upgrade in its Mojo Grade from Strong Sell to Hold, underscores a renewed investor interest and a potential re-rating of the micro-cap pharmaceutical player amid a challenging sector backdrop." }, { "title": "Are Aarey Drugs & Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-aarey-drugs-pharmaceuticals-ltd-latest-results-good-or-bad-4028143", "imagepath": "", "date": "2026-06-01 19:29:43", "description": "Aarey Drugs & Pharmaceuticals Ltd has reported its financial results for the quarter ending March 2026, showcasing a significant increase in both revenue and net profit compared to the previous year. Specifically, net sales reached ₹189.47 crores, reflecting a year-on-year growth of 75.27%, while net profit surged to ₹1.56 crores, marking a 231.91% increase. This performance indicates a strong revenue momentum, with the company achieving its highest quarterly revenue in recent history.\n\nHowever, despite the impressive revenue growth, the company's operating profit margin remains low at 2.29%, which highlights ongoing cost pressures that have affected profitability. The operating profit before depreciation, interest, and tax (excluding other income) was ₹4.34 crores, indicating a substantial increase in absolute terms but still translating to a modest margin. The profit after tax (PAT) margin of 0.82% is par..." }, { "title": "Aarey Drugs & Pharmaceuticals Ltd Reports Strong Quarterly Turnaround with Positive Financial Trend", "link": "https://www.marketsmojo.com/news/stocks-in-action/aarey-drugs-pharmaceuticals-ltd-reports-strong-quarterly-turnaround-with-positive-financial-trend-4026453", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_fintrenddot_4026453.png", "date": "2026-06-01 11:01:28", "description": "Aarey Drugs & Pharmaceuticals Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, reversing a previously negative trend with its highest quarterly revenue and profit metrics to date. This improvement has prompted an upgrade in its Mojo Grade from Strong Sell to Sell, signalling cautious optimism amid ongoing market challenges." }, { "title": "Aarey Drugs Q4 FY26: Stellar Revenue Surge Masks Persistent Margin Struggles", "link": "https://www.marketsmojo.com/news/result-analysis/aarey-drugs-q4-fy26-stellar-revenue-surge-masks-persistent-margin-struggles-4026741", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AareyDrugsPharm_quaterlyResult_4026741.png", "date": "2026-06-01 10:49:12", "description": "Aarey Drugs & Pharmaceuticals Ltd. reported a dramatic revenue surge in Q4 FY26, with net sales jumping 96.48% quarter-on-quarter to ₹189.47 crores—the highest quarterly figure in recent history. However, the impressive topline growth failed to translate into meaningful bottom-line expansion, as net profit stood at ₹1.56 crores, up 173.68% QoQ but still reflecting wafer-thin margins. The micro-cap pharmaceutical company, with a market capitalisation of ₹222.00 crores, continues to grapple with structural profitability challenges despite strong revenue momentum." } ], "total": 603, "sid": "933527", "stock_news_url": "https://www.marketsmojo.com/news/aarey-drugs-pharmaceuticals-933527" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "02-Jun-2026", "details": "As per Attachment", "source": "BSE" }, { "caption": "Audited Standalone Financial Results Of The Company For The Fourth Quarter And Year Ended March 31 2026", "datetime": "30-May-2026", "details": "As per Attachment", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday 30Th May 2026", "datetime": "30-May-2026", "details": "Outcome of Board Meeting held on Saturday 30th May 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Aarey Drugs & Pharmaceuticals Ltd has declared <strong>1%</strong> dividend, ex-date: 13 Dec 18", "dt": "2018-12-13", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Aarey Drugs & Pharmaceuticals Ltd has announced <strong>1:5</strong> bonus issue, ex-date: 25 Jun 12", "dt": "2012-06-25", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Aarey Drugs & Pharmaceuticals Ltd has announced <strong>2:1</strong> rights issue, ex-date: 19 Jan 12", "dt": "2012-01-19", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

1 June: Strong quarterly turnaround reported with record net sales and profits

1 June: Downgrade to Strong Sell amid mixed financial and technical signals

2 June: Valuation shift prompts upgrade from Strong Sell to Hold

5 June: Week closes at Rs.77.52, up 1.00% for the week

Week Open

Rs.76.75

Week Close<...

Read full news article

Aarey Drugs & Pharmaceuticals Ltd is Rated Hold

2026-06-12 10:10:05

Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Below All Moving Averages and Now at Lower Circuit: Aarey Drugs & Pharmaceuticals Ltd Loses 4.7% in a Single Session

2026-06-11 11:00:16

At Rs 74.51, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 11 Jun 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock.

Read full news article

Aarey Drugs & Pharmaceuticals Ltd: Valuation Shift Signals Renewed Price Attractiveness

2026-06-02 08:04:16

Aarey Drugs & Pharmaceuticals Ltd has witnessed a notable transformation in its valuation metrics, shifting from a previously risky profile to one deemed attractive by recent assessments. This change, coupled with a significant upgrade in its Mojo Grade from Strong Sell to Hold, underscores a renewed investor interest and a potential re-rating of the micro-cap pharmaceutical player amid a challenging sector backdrop.

Read full news article

Are Aarey Drugs & Pharmaceuticals Ltd latest results good or bad?

2026-06-01 19:29:43

Aarey Drugs & Pharmaceuticals Ltd has reported its financial results for the quarter ending March 2026, showcasing a significant increase in both revenue and net profit compared to the previous year. Specifically, net sales reached ₹189.47 crores, reflecting a year-on-year growth of 75.27%, while net profit surged to ₹1.56 crores, marking a 231.91% increase. This performance indicates a strong revenue momentum, with the company achieving its highest quarterly revenue in recent history. However, despite the impressive revenue growth, the company's operating profit margin remains low at 2.29%, which highlights ongoing cost pressures that have affected profitability. The operating profit before depreciation, interest, and tax (excluding other income) was ₹4.34 crores, indicating a substantial increase in absolute terms but still translating to a modest margin. The profit after tax (PAT) margin of 0.82% is par...

Read full news article

Aarey Drugs & Pharmaceuticals Ltd Reports Strong Quarterly Turnaround with Positive Financial Trend

2026-06-01 11:01:28

Aarey Drugs & Pharmaceuticals Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, reversing a previously negative trend with its highest quarterly revenue and profit metrics to date. This improvement has prompted an upgrade in its Mojo Grade from Strong Sell to Sell, signalling cautious optimism amid ongoing market challenges.

Read full news article

Aarey Drugs Q4 FY26: Stellar Revenue Surge Masks Persistent Margin Struggles

2026-06-01 10:49:12

Aarey Drugs & Pharmaceuticals Ltd. reported a dramatic revenue surge in Q4 FY26, with net sales jumping 96.48% quarter-on-quarter to ₹189.47 crores—the highest quarterly figure in recent history. However, the impressive topline growth failed to translate into meaningful bottom-line expansion, as net profit stood at ₹1.56 crores, up 173.68% QoQ but still reflecting wafer-thin margins. The micro-cap pharmaceutical company, with a market capitalisation of ₹222.00 crores, continues to grapple with structural profitability challenges despite strong revenue momentum.

Read full news article